In a cohort of primary HER2+ breast cancer patients treated with either chemotherapy and trastuzumab or lapatinib (or both combined), no correlation to 611-CTF expression was seen with neoadjuvant lapatinib or trastuzumab treatment. The gene discussed is ERBB2; the disease is breast carcinoma.